Morgan Stanley’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.1M | Sell |
1,113,526
-97,228
| -8% | -$2.1M | ﹤0.01% | 2780 |
|
|
2025
Q4 | $28.9M | Sell |
1,210,754
-325,334
| -21% | -$6.64M | ﹤0.01% | 2601 |
|
|
2025
Q3 | $20.9M | Buy |
1,536,088
+66,284
| +5% | +$689K | ﹤0.01% | 2854 |
|
|
2025
Q2 | $12M | Buy |
1,469,804
+682,724
| +87% | +$5.83M | ﹤0.01% | 3280 |
|
|
2025
Q1 | $6.18M | Buy |
787,080
+237,166
| +43% | +$2.75M | ﹤0.01% | 3749 |
|
|
2024
Q4 | $8.19M | Sell |
549,914
-164,542
| -23% | -$2.69M | ﹤0.01% | 3566 |
|
|
2024
Q3 | $10.9M | Buy |
714,456
+268,576
| +60% | +$4.23M | ﹤0.01% | 3358 |
|
|
2024
Q2 | $6.79M | Sell |
445,880
-429,002
| -49% | -$6.92M | ﹤0.01% | 3644 |
|
|
2024
Q1 | $16.5M | Sell |
874,882
-527,908
| -38% | -$9.13M | ﹤0.01% | 2897 |
|
|
2023
Q4 | $26.8M | Buy |
1,402,790
+793,804
| +130% | +$12.7M | ﹤0.01% | 3085 |
|
|
2023
Q3 | $10.9M | Sell |
608,986
-11,548
| -2% | -$232K | ﹤0.01% | 3044 |
|
|
2023
Q2 | $12.6M | Buy |
620,534
+64,453
| +12% | +$1.23M | ﹤0.01% | 2941 |
|
|
2023
Q1 | $10.1M | Buy |
556,081
+9,732
| +2% | +$186K | ﹤0.01% | 3125 |
|
|
2022
Q4 | $11.3M | Buy |
546,349
+193,288
| +55% | +$5.32M | ﹤0.01% | 2954 |
|
|
2022
Q3 | $9.24M | Sell |
353,061
-230,635
| -40% | -$6.1M | ﹤0.01% | 3064 |
|
|
2022
Q2 | $14.8M | Buy |
583,696
+333,066
| +133% | +$8.16M | ﹤0.01% | 2615 |
|
|
2022
Q1 | $7.91M | Sell |
250,630
-1,183,774
| -83% | -$39.7M | ﹤0.01% | 3181 |
|
|
2021
Q4 | $58M | Buy |
1,434,404
+1,300,591
| +972% | +$50.5M | 0.01% | 1233 |
|
|
2021
Q3 | $4.67M | Sell |
133,813
-135,645
| -50% | -$4.22M | ﹤0.01% | 3791 |
|
|
2021
Q2 | $7.4M | Buy |
269,458
+94,862
| +54% | +$2.71M | ﹤0.01% | 3352 |
|
|
2021
Q1 | $4.9M | Buy |
174,596
+127,334
| +269% | +$4.43M | ﹤0.01% | 3431 |
|
|
2020
Q4 | $1.23M | Buy |
47,262
+18,436
| +64% | +$446K | ﹤0.01% | 4539 |
|
|
2020
Q3 | $494K | Sell |
28,826
-62,756
| -69% | -$1.4M | ﹤0.01% | 4652 |
|
|
2020
Q2 | $2.27M | Buy |
91,582
+88,341
| +2,726% | +$2.38M | ﹤0.01% | 3483 |
|
|
2020
Q1 | $45K | Sell |
3,241
-41,495
| -93% | -$516K | ﹤0.01% | 5502 |
|
|
2019
Q4 | $452K | Buy |
44,736
+33,939
| +314% | +$285K | ﹤0.01% | 4983 |
|
|
2019
Q3 | $98K | Sell |
10,797
-88,009
| -89% | -$707K | ﹤0.01% | 5451 |
|
|
2019
Q2 | $785K | Buy |
98,806
+88,716
| +879% | +$888K | ﹤0.01% | 4359 |
|
|
2019
Q1 | $125K | Sell |
10,090
-40,846
| -80% | -$443K | ﹤0.01% | 5295 |
|
|
2018
Q4 | $549K | Buy |
50,936
+35,192
| +224% | +$411K | ﹤0.01% | 4728 |
|
|
2018
Q3 | $220K | Buy |
15,744
+3,801
| +32% | +$48.5K | ﹤0.01% | 5414 |
|
|
2018
Q2 | $146K | Buy |
11,943
+5,940
| +99% | +$93.2K | ﹤0.01% | 5646 |
|
|
2018
Q1 | $93K | Buy |
+6,003
| New | +$100K | ﹤0.01% | 5725 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Morgan Stanley's RCUS Position: Q1 2026 in Review
Morgan Stanley reduced its Arcus Biosciences (RCUS) stake by 8% in Q1 2026, selling an estimated $2.1M and leaving 1,113,526 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2780.
Morgan Stanley first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $58M in Q4 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Morgan Stanley held 1,113,526 shares of Arcus Biosciences worth $24.1M as of Q1 2026.
- Morgan Stanley sold 97,228 Arcus Biosciences shares in Q1 2026, an estimated $2.1M.
- Arcus Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2780 holding.
- Morgan Stanley first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- Morgan Stanley's Arcus Biosciences position peaked at $58M in Q4 2021.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.